



## DEVELOPMENT AND VALIDATION OF REVERSE PHASE HIGH PERFORMANCE LIQUID CHROMATOGRAPHY METHOD FOR SIMULTANEOUS ESTIMATION OF TAPENTADOL HYDROCHLORIDE AND LORNOXICAM IN SYNTHETIC MIXTURE.

Prajapati Arun M<sup>1</sup>, Soni Umang P<sup>1\*</sup>

<sup>1</sup>Department of Quality Assurance, S. K. Patel College of Pharmaceutical Education and Research, Ganpat University, Ganpat Vidyanagar, Mehsana, Gujarat, India.

Date Received:

19-Mar-2014

Date of Accepted:

13-Apr-2014

Date Published:

23-Apr-2014

### Abstract:

A simple, precise, accurate and rapid reverse phase high performance liquid chromatographic method has been developed for the estimation of Tapentadol hydrochloride (TAP) and Lornoxicam (LOR) in combined synthetic mixture. The chromatographic separation was attained on reverse phase C<sub>18</sub> column (Phenomenex C<sub>18</sub>, 250 mm × 4.6 mm, 5μm) as stationary phase with mobile phase comprising phosphate buffer (pH-3.5) : acetonitrile (65:35, v/v) with a flow rate of 1 ml/min. Quantification was achieved with Photo Diode Array detector at 275 nm. The retention times of TAP and LOR were 2.24 min and 4.91 min respectively. The linearity of TAP and LOR were in the range of 5-35 μg/ml and 2-12 μg/ml respectively. The method was successfully applied to synthetic mixture because no chromatographic interferences from the mixture excipients were found. The method retained its accuracy and precision when the standard addition technique was applied.

### Keywords:

Tapentadol hydrochloride, Lornoxicam, RP-HPLC, Validation.

### Introduction

Tapentadol hydrochloride (TAP)<sup>[1]</sup> is chemically 3-[(1R,2R)-3-(dimethylamino)-1-ethyl-2-methylpropyl] phenol hydrochloride (figure 1), a centrally acting analgesic. It is not official in any pharmacopoeia. Literature survey reveals HPLC, spectrophotometric method for estimation tapentadol hydrochloride in single dosage form.<sup>[2,3,4]</sup> Literature survey also reveals spectrophotometric<sup>[5]</sup>, HPTLC<sup>[6]</sup> and HPLC<sup>[7]</sup> methods for determination of tapentadol hydrochloride with other drugs in combination. Lornoxicam (LOR)<sup>[8]</sup> is (3E)-6-chloro-3-[hydroxy(pyridin-2-ylamino)methylene]-2-methyl-2,3-dihydro-4H-thieno[2,3-e][1,2]thiazin-4-one 1,1-dioxide (figure 2), a non-steroidal anti inflammatory agent (NSAID). It is not official in any pharmacopoeia. Literature survey reveals spectrophotometric<sup>[9]</sup>, HPTLC<sup>[10]</sup> and HPLC<sup>[11]</sup> methods for determination of lornoxicam in single dosage form. Literature survey

also reveals spectrophotometric<sup>[12]</sup>, HPLC<sup>[13]</sup> and HPTLC<sup>[14]</sup> methods for determination of lornoxicam with other drugs in combination. The combination of these two drugs is not official in any pharmacopoeia; hence no official method is available for the simultaneous estimation of tapentadol hydrochloride and lornoxicam in their combined synthetic mixture. There has been no report in literature on the simultaneous determination of tapentadol hydrochloride and lornoxicam in synthetic mixture. The present work describes the development of validated RP-HPLC method, which can quantify these components simultaneously from a combined synthetic mixture. The proposed RP HPLC method was validated in accordance with ICH guidelines<sup>[15]</sup>, by assessing its selectivity, linearity, accuracy, precision, and limits of detection and quantification.

## MATERIALS AND METHODS

### APPARATUS

The separation was carried out using a RP-HPLC instrument equipped with a UV-Visible detector, a photodiode array detector, and LC-solution software (Shimadzu, LC-2010CHT, Japan.), auto sampler, Phenomenex (Torrance, CA) C18 column (150 mm x 4.6 mm i.d, 5 µm particle size) was used as stationary phase. Analytical balance (Sartorius CP224S, Germany), Triple distillation unit consisting of borosilicate glass, Digital pH meter (LI 712 pH analyzer, Elico Ltd., Ahmedabad), Ultra sonic cleaner (Frontline FS 4, Mumbai, India) were used in the study.

### REAGENTS AND MATERIALS

Tapentadol hydrochloride (TAP) standard was kindly gifted by Zydus-Cadila Pharmaceuticals Ltd., Ahmedabad, Gujarat, India. Lornoxicam (LOR) standard was kindly gifted by Torrent Pharmaceuticals Ltd., Ahmedabad, Gujarat. The synthetic mixture containing 50 mg TAP and 8 mg LOR was prepared in the laboratory. HPLC grade methanol (Merck Ltd., Mumbai, India), HPLC grade acetonitrile (Finar Chemicals Ltd., Mumbai, India) were used in the study. The water for RP-HPLC was prepared by triple glass distillation and filtered through a nylon 0.45 µm – 47 mm membrane filter. Nylon 0.45 µm – 47 mm membrane filter (Gelman Laboratory, Mumbai, India) and Whatman filter paper no. 41. (Whatman International Ltd., England) were used in the study.

### PREPARATION OF SOLUTIONS & REAGENTS:

#### Preparation of TAP and LOR Standard Stock Solutions

An accurately weighed quantity of both tapentadol hydrochloride and lornoxicam standard (5 mg) were weighed and transferred to 100 ml separate volumetric flasks and dissolved in methanol. The flasks were shaken and volumes were made up to mark with methanol to give a solution having concentration 50 µg/ml for both of the drugs.

#### Preparation of Synthetic mixture

Tapentadol hydrochloride (50 mg) and Lornoxicam (8 mg) were taken and then both the drug were mixed with Starch, Lactose, Magnesium Stearate and Talc. Total 100 mg of mixture was prepared.

#### Preparation of Sample Solution

The powder of synthetic mixture equivalent to 50 mg of TAP and 8 mg of LOR transferred to 100 mL volumetric flask. 50 mL methanol was added and sonicated for 20 min. The solution was filtered through whatman filter paper No. 41 and the volume was adjusted up to the

mark with methanol (HPLC Grade) to prepare 50 µg/mL of TAP and 8 µg/mL of LOR. From the above solution, 0.5mL was taken and was transferred to 10 mL volumetric flask and volume was adjusted up to the mark to obtain solution having 25 µg/mL of TAP and 8 µg/mL LOR. An aliquot (20 µl) of sample solution was injected under the operating chromatographic condition and responses were recorded.

#### Preparation of 0.02M Phosphate buffer solution (pH 3.5)

Phosphate buffer (0.02 M KH<sub>2</sub>PO<sub>4</sub>, pH 3.5) was prepared by dissolving accurately weighed 0.272 g of potassium dihydrogen phosphate in 100 ml HPLC-grade water and the pH adjusted to 3.5 by diluted ortho-phosphoric acid.

#### Preparation of Calibration Curve

Aliquots equivalent to 1.0, 2.0, 3.0, 4.0, 5.0, and 6.0 ml standard solution of TAP and 0.4, 0.8, 1.2, 1.6, 2.0 and 2.4 ml standard solution of LOR were transferred into a series of 10 ml volumetric flasks separately and volume was adjusted to the mark with solvent (Methanol) to get concentrations 5, 10, 15, 20, 25 and 30 µg/ml of TAP and 2, 4, 6, 8, 10 and 12 µg/ml of LOR. 20 µl of each of the solution were injected into HPLC system and analyzed. Calibration curve was obtained by plotting respective peak area against concentration in µg/ml and the regression equation was computed.

#### Selection of detection wavelength

By preparing appropriate solution concentration of each drug (TAP and LOR) both drugs were scanned over the range of 200 to 400 nm in spectrum mode. While studying the overlay spectra, it was observed that these 2 drugs show optimum absorbance at 275 nm. This wavelength was used for detection of TAP and LOR.

#### Chromatographic Condition

**Stationary phase:** C18 column (150 mm x 4.6 mm i.d., 5 µm particle size) was used at ambient temperature (40 °C).

**Mobile Phase:** Phosphate buffer pH 3.5 : Acetonitrile [65 : 35, v/v/v]

**Flow rate:** 1.0 mL/min

**Injection volume:** 20 µL

**Detection:** The elution was monitored at 275 nm using PDA detector.

### METHOD VALIDATION

The method was validated in compliance with ICH guidelines<sup>[15]</sup>.

### Accuracy (recovery study)

To study the accuracy of the proposed method, recovery studies were carried out by standard addition method at three different levels (75%, 100%, and 125%). A known amount of drug was added to reanalyzed sample powder and percentage recoveries were calculated.

### Method Precision (Repeatability)

The precision of the instrument was checked by repeated injection ( $n = 6$ ) of standard solutions of TAP (10 µg/ml) and LOR (4 µg/ml) under the same chromatographic condition and measurement of peak area, retention time and tailing factor. The low %RSD values (less than 2%) indicates that proposed method is repeatable.

### Intermediate Precision (Reproducibility)

The intra-day and inter-day precision of the proposed method was determined by analyzing the corresponding responses 3 times on the same day and on 3 different days over a period of 1 week for 3 different concentrations of standard solutions of TAP (5, 10, 15 µg/ml) and LOR (2, 4, 6 µg/ml). The result was reported in terms of relative standard deviation (% RSD).

### Limit of Detection and Limit of Quantification

LOD and LOQ of drugs can be calculated using the following equations designated by International Conference on Harmonization (ICH) guidelines.<sup>[15]</sup>

$$\text{LOD} = 3.3 \times \sigma/S$$

$$\text{LOQ} = 10 \times \sigma/S$$

Where,  $\sigma$  = the standard deviation of the response and  $S$  = slope of the calibration curve.

### Robustness

The robustness was studied by analyzing the same samples of TAP and LOR by deliberate variations in the method parameters. The change in the responses of TAP and LOR were noted. Robustness of the method was studied by changing the composition of mobile phase by  $\pm 2\%$  of organic solvent, flow rate by  $\pm 0.2$  ml/min and column oven temperature by  $40 \pm 2^\circ\text{C}$ . The parameters used in system suitability test were asymmetry of the chromatographic peak, tailing factor and theoretical plates, as %RSD of peak area for replicate injections.

## RESULTS AND DISCUSSION

A RP-HPLC method was developed and validated for the determination of TAP and LOR in combined synthetic mixture on a C18 column (150 mm x 4.6 mm i.d., 5 µm particle size) with variable wavelength detection at 275 nm. The retention times of TAP and LOR were 2.244 and 4.918 min, respectively. Linear correlation was obtained between area and concentration of TAP and LOR in the concentration range of 5-35 µg/ml and 2-12 µg/ml respectively for both drugs. The low RSD value of

intra-day (0.30-0.47 % for TAP and 0.28-0.70 % for LOR) and inter-day (0.42-0.62 % for LOR and 0.80-0.90 % for LOR) at 275nm, reveal that proposed method is precise. The limit of detection (LOD) and limit of quantification (LOQ) for TAP and LOR were found to be 0.11 and 0.33 µg/ml and 0.04 and 0.13 µg/ml, respectively. These data show that method is sensitive for the determination of TAP and LOR. The recovery experiment was performed by the standard addition method. The mean recoveries were  $99.75 \pm 0.52$  and  $98.07 \pm 0.49$  for TAP and LOR, respectively (Table 2). The results of recovery studies indicate that the proposed method is highly accurate. The proposed validated method was successfully applied to determine TAP and LOR in combined synthetic mixture. No interference of the excipients with the retention time of drugs appeared; hence the proposed method is applicable for the routine simultaneous estimation of TAP and LOR.

## CONCLUSION

Rapid separation of TAP and LOR was successfully attained with a relatively short retention time, provides good resolution, good peak shape, gives reliable and highly reproducible results on C18 HPLC column. In this proposed RP-HPLC method, the linearity was observed in the concentration range of 5-35 µg/ml and 2-12 µg/ml respectively for TAP and LOR with co-efficient of correlation, ( $r^2$ ) = 0.998 and ( $r^2$ ) = 0.999 for TAP and LOR, respectively at 275 nm. The results of the analysis of combined synthetic mixture by the proposed method are highly reproducible and reliable. The method can be used for the routine analysis of the TAP and LOR in combined synthetic mixture without any interference of excipients.

## ACKNOWLEDGEMENT

The authors are thankful to Zydus-Cadila Pharmaceuticals Ltd., Ahmedabad, and Torrent Pharmaceuticals Ltd., Ahmedabad, for providing gift sample of TAP and LOR, respectively for carrying out the research work. The authors are highly thankful to Shree S. K. Patel College of Pharmaceutical Education and Research, Ganpat University, Ganpat Vidyanagar – 384012, Mehsana, Gujarat, India for providing all the facilities to carry out the research work.




Figure 1 Chromatogram of TAP (50µg/ml) and LOR (8µg/ml) at 275 nm

Figure 1: Chromatogram of TAP (50 µg/ml) and LOR (8µg/ml)

| PARAMETERS                                        | TAP                    | LOR                   |
|---------------------------------------------------|------------------------|-----------------------|
| Concentration range (µg/ml)                       | 5-35                   | 2-12                  |
| Regression equation<br>(y = mx + c)               | y = 3412.18x + 10863.5 | y = 7671.9x + 6430.38 |
| Slope (m)                                         | 3412                   | 7671.9                |
| Intercept (c)                                     | 10863.5                | 6430.38               |
| Correlation Coefficient (r <sup>2</sup> )         | 0.998                  | 0.999                 |
| Accuracy (Recovery ± S.D.)<br>(n = 3)             | 99.75 ± 0.52           | 98.07 ± 0.49          |
| Method precision (Repeatability) (%<br>RSD, n= 6) | 0.916                  | 0.782                 |
| Intraday (n = 3) (% RSD)                          | 0.30-0.47              | 0.28-0.70             |
| Interday(n = 3) (% RSD)                           | 0.42-0.62              | 0.80-0.90             |
| LOD(µg/ml)                                        | 0.11                   | 0.04                  |
| LOQ (µg/ml)                                       | 0.33                   | 0.13                  |
| Assay ± S. D. (n = 3)                             | 100.69 ± 0.85          | 101.46 ± 0.37         |

Table 1: Data Showing Linearity and Precision of the Developed Method

| Drug | Level | Amount<br>taken<br>(µg/ml) | Amount<br>added<br>(%) | % Mean recovery ± S.D.<br>(n = 3) |
|------|-------|----------------------------|------------------------|-----------------------------------|
| TAP  | I     | 10                         | 75                     | 100.18 ± 0.55                     |
|      | II    | 10                         | 100                    | 99.67 ± 0.77                      |
|      | III   | 10                         | 125                    | 99.42 ± 0.26                      |
| LOR  | I     | 1.6                        | 75                     | 96.33 ± 0.59                      |
|      | II    | 1.6                        | 100                    | 98.45 ± 0.51                      |
|      | III   | 1.6                        | 125                    | 99.44 ± 0.38                      |

Table 2: Recovery Data

| Drug | Label Claim<br>(mg) | Amount Found<br>(mg) | % Label claim ± S.D.<br>(n=3) |
|------|---------------------|----------------------|-------------------------------|
| TAP  | 50                  | 50.34                | 100.69 ± 0.85                 |
| LOR  | 8                   | 8.10                 | 101.46 ± 0.37                 |

Table 3: Results of Analysis of Tablet Dosage Forms Containing TAP and LOR

| Parameters           | TAP $\pm$ % CV (n=6) | LOR $\pm$ % CV (n=6) |
|----------------------|----------------------|----------------------|
| Retention time (min) | 2.244 $\pm$ 0.16     | 4.918 $\pm$ 0.24     |
| Tailing factor       | 1.032 $\pm$ 1.262    | 1.388 $\pm$ 1.274    |
| Theoretical plates   | 2275 $\pm$ 1.698     | 4059 $\pm$ 1.846     |
| Resolution           | 5.441 $\pm$ 1.367    |                      |

Table 4: System suitability test parameters for the proposed RP-HPLC method




Figure 2 Linearity curve of TAP (5-35 µg/ml)




Figure 3 Linearity curve of LOR (2-12 µg/ml)

#### REFERENCES:

1. Available from URL: <http://www.drugbank.ca/drugs/DB06204>
2. Omkar S. and Priti M., Development and Validation of RP- HPLC, UV-Spectrometric and Spectrophotometric Method for Estimation of Tapentadol Hydrochloride in Bulk and in Laboratory Sample of Tablet Dosage Form, Journal of Chemical and Pharmaceutical Research, (9), 2012, 4134-4140.
3. Mokhtar M., Hamed M., Sherin H., Aya M., Spectrophotometric Methods for Determination of Tapentadol Hydrochloride, Journal of Applied Pharmaceutical Science Vol. 3 (03), March, 2013, 122-125.
4. Anandakumar K., Narendra B., Development of Difference Spectroscopic Method for the Estimation of Tapentadol Hydrochloride in Bulk and in Formulation, International Journal of PharmTech Research CODEN (USA): Vol.4, No.4, Oct-Dec 2012, 1586-1590.
5. Vishal K. and Ashwin A., Development And Validation Of Spectrophotometric Methods For Simultaneous Estimation Of Paracetamol And Tapentadol In Combined Pharmaceutical Dosage Form, International Journal of PharmTech Research CODEN (USA) Vol.5, No.2, April-June 2013, 414-419.

6. Dharmishtha B., Kavita G., Nehal K., Hitesh V., Ashok P., Gunjan P., Shruti D., Shailesh M., Development And Validation Of Hptlc Method For Simultaneous Estimation Of Tapentadol Hydrochloride And Paracetamol In Their Tablet Dosage Form, Indo American Journal Of Pharmaceutical Research, Oct 2013.
7. Bhupendrasinh R., Bimal P., Nurrudin J., Digbijay K., Nitin S., Development And Validation Of Hplc Method For Simultaneous Estimation Of Paracetamol And Tapentadol Hydrochloride In Their Combined Dosage Form, Inventi Rapid: Pharm Analysis & Quality Assurance publication date: May 2013.
8. Maryadele J O Neil, The Merck Index: An Encyclopedia of Chemicals, Drugs and Biologicals, Merck and Co. Inc., Fourteenth Edition, White House Station, New Jersey, USA, 2006, 5582.
9. Sunit S, Ranjit G, Sachin P, Amulya B, Ranjit M. Development of Ultraviolet Spectrophotometric Method for Analysis of Lornoxicam in Solid Dosage Forms. Tropical Journal of Pharmaceutical Research, 11 (2), April 2012, 269-273.
10. Shital B, Santosh G, Padmanabh D, Navjot G. High performance thin layer chromatographic determination of lornoxicam in human plasma. Journal of Chemical, Biological and Physical Sciences., 2(1), 2011-2012, 279-283.
11. Shital B, Nikhil K. Extractionless High-Performance Liquid Chromatographic method for determination of lornoxicam in human plasma. Asian Journal of Pharmaceutical and Clinical Research, 5(1), 2012, 122-124.
12. Rele V, Warkar B. Estimation of Lornoxicam and Diacerin in dosage form by Simultaneous equation & Q-analysis method using UV Spectroscopic technique. International Journal of Pharma and Bio Sciences., 2(2), 2011, 124-129.
13. Pankaj K, Shubhanjali S, Subudhia B, Ashok G. Bioanalytical Method development & Validation for the Simultaneous estimation of Thiocolchicoside & Lornoxicam in Human plasma and in Pharmaceutical dosage form by RP-HPLC. International Journal of Pharmacy and Pharmaceutical Sciences, 4(3), 2012, 252-259.
14. Madhusmita S, Pratima S, Asawaree H, Rahul R, Vishnu C, Bhanudas K. Development & Validation of HPTLC method for the simultaneous estimation of Lornoxicam & Thiocolchicoside in combined dosage form. Pharmaceutical Methods-Academic Journal, 2(3), 2011, 178.
15. The International Conference on Harmonization, Q2 (R1), Validation of Analytical Procedure, Text and Methodology, 2005.